Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has challenged healthcare globally. An acute increase in the number of hospitalized patients has necessitated a rigorous reorganization of hospital care, thereby creating circumstances that previously have been identified as facilitating prescribing errors (PEs), e.g. a demanding work environment, a high turnover of doctors, and prescribing beyond expertise. Hospitalized COVID-19 patients may be at risk of PEs, potentially resulting in patient harm. We determined the prevalence, severity, and risk factors for PEs in post–COVID-19 patients, hospitalized during the first wave of COVID-19 in the Netherlands, 3 months after discharge. Methods This prospective observational cohort study recruited patients who visited a post-COVID-19 outpatient clinic of an academic hospital in the Netherlands, 3 months after COVID-19 hospitalization, between June 1 and October 1 2020. All patients with appointments were eligible for inclusion. The prevalence and severity of PEs were assessed in a multidisciplinary consensus meeting. Odds ratios (ORs) were calculated by univariate and multivariate analysis to identify independent risk factors for PEs. Results Ninety-eight patients were included, of whom 92% had ≥1 PE and 8% experienced medication-related harm requiring an immediate change in medication therapy to prevent detoriation. Overall, 68% of all identified PEs were made during or after the COVID-19 related hospitalization. Multivariate analyses identified ICU admission (OR 6.08, 95% CI 2.16–17.09) and a medical history of COPD / asthma (OR 5.36, 95% CI 1.34–21.5) as independent risk factors for PEs. Conclusions PEs occurred frequently during the SARS-CoV-2 pandemic. Patients admitted to an ICU during COVID-19 hospitalization or who had a medical history of COPD / asthma were at risk of PEs. These risk factors can be used to identify high-risk patients and to implement targeted interventions. Awareness of prescribing safely is crucial to prevent harm in this new patient population. Supplementary Information The online version contains supplementary material available at 10.1186/s12873-022-00588-7.
【저자키워드】 COVID-19, clinical pharmacology, Prescribing errors, Pharmacotherapeutic stewardship, 【초록키워드】 coronavirus disease, SARS-CoV-2, Asthma, coronavirus, pandemic, therapy, Hospitalized, Hospitalization, severity, hospital, risk, risk factor, discharge, ICU, COPD, Prevalence, healthcare, Patient, ICU admission, Awareness, COVID-19 hospitalization, medication, First wave, Care, patients, Analysis, COVID-19 patient, Netherlands, outpatient clinic, Consensus, acute respiratory syndrome, supplementary material, 95% CI, multivariate, independent risk factor, targeted interventions, patient population, high-risk patient, Prevent, Result, resulting, identify, occurred, recruited, can be used, calculated, hospitalized patient, increase in, cause, creating, eligible, for inclusion, prospective observational cohort, the SARS-CoV-2, were assessed, 【제목키워드】 severity, risk factor, Prevalence, Patient, outpatient clinic, prescribing,